Immunome reported that its antibody reduced the risk of disease worsening or death by 84% in a Phase 3 trial for advanced desmoid tumors, achieving the study’s primary endpoint. The company said it plans to prepare an FDA submission next year based on the data. Desmoid tumors are rare, locally aggressive soft-tissue neoplasms with limited systemic treatment options; an 84% reduction in progression or death represents a large clinical effect for this indication. The result could reshape competitive dynamics for therapies serving rare solid tumors.